G-Y Ban1, K Cho2,3, S-H Kim1, M K Yoon1, J-H Kim1, H Y Lee4, Y S Shin1, Y-M Ye1, J-Y Cho2,5, H-S Park1. 1. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. 2. Department of Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea. 3. Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Statistics, Clinical Trial Center, Ajou University Medical Center, Suwon, Korea. 5. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: To date, there has been no reliable in vitro test to diagnose aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: To investigate potential diagnostic biomarkers for AERD using metabolomic analysis. METHODS: An untargeted profile of serum from asthmatics in the first cohort (group 1) comprising 45 AERD, 44 patients with aspirin-tolerant asthma (ATA), and 28 normal controls was developed using the ultra-high-performance liquid chromatography (UHPLC)/Q-ToF MS system. Metabolites that discriminate AERD from ATA were quantified in both serum and urine, which were collected before (baseline) and after the lysine-aspirin bronchoprovocation test (Lys-ASA BPT). The serum metabolites were validated in the second cohort (group 2) comprising 50 patients with AERD and 50 patients with ATA. RESULTS: A clear discrimination of metabolomes was found between patients with AERD and ATA. In group 1, serum levels of LTE4 and LTE4 /PGF2 α ratio before and after the Lys-ASA BPT were significantly higher in patients with AERD than in patients with ATA (P < 0.05 for each), and urine baseline levels of these two metabolites were significantly higher in patients with AERD. Significant differences of serum metabolite levels between patients with AERD and ATA were replicated in group 2 (P < 0.05 for each). Moreover, serum baseline levels of LTE4 and LTE4 /PGF2 α ratio discriminated AERD from ATA with 70.5%/71.6% sensitivity and 41.5%/62.8% specificity, respectively (AUC = 0.649 and 0.732, respectively P < 0.001 for each). Urine baseline LTE4 levels were significantly correlated with the fall in FEV1 % after the Lys-ASA BPT in patients with AERD (P = 0.008, r = 0.463). CONCLUSIONS AND CLINICAL RELEVANCE: Serum metabolite level of LTE4 and LTE4 /PGF2 α ratio was identified as potential in vitro diagnostic biomarkers for AERD using the UHPLC/Q-ToF MS system, which were closely associated with major pathogenetic mechanisms underlying AERD.
BACKGROUND: To date, there has been no reliable in vitro test to diagnose aspirin-exacerbated respiratory disease (AERD). OBJECTIVE: To investigate potential diagnostic biomarkers for AERD using metabolomic analysis. METHODS: An untargeted profile of serum from asthmatics in the first cohort (group 1) comprising 45 AERD, 44 patients with aspirin-tolerant asthma (ATA), and 28 normal controls was developed using the ultra-high-performance liquid chromatography (UHPLC)/Q-ToF MS system. Metabolites that discriminate AERD from ATA were quantified in both serum and urine, which were collected before (baseline) and after the lysine-aspirin bronchoprovocation test (Lys-ASA BPT). The serum metabolites were validated in the second cohort (group 2) comprising 50 patients with AERD and 50 patients with ATA. RESULTS: A clear discrimination of metabolomes was found between patients with AERD and ATA. In group 1, serum levels of LTE4 and LTE4 /PGF2 α ratio before and after the Lys-ASA BPT were significantly higher in patients with AERD than in patients with ATA (P < 0.05 for each), and urine baseline levels of these two metabolites were significantly higher in patients with AERD. Significant differences of serum metabolite levels between patients with AERD and ATA were replicated in group 2 (P < 0.05 for each). Moreover, serum baseline levels of LTE4 and LTE4 /PGF2 α ratio discriminated AERD from ATA with 70.5%/71.6% sensitivity and 41.5%/62.8% specificity, respectively (AUC = 0.649 and 0.732, respectively P < 0.001 for each). Urine baseline LTE4 levels were significantly correlated with the fall in FEV1 % after the Lys-ASA BPT in patients with AERD (P = 0.008, r = 0.463). CONCLUSIONS AND CLINICAL RELEVANCE: Serum metabolite level of LTE4 and LTE4 /PGF2 α ratio was identified as potential in vitro diagnostic biomarkers for AERD using the UHPLC/Q-ToF MS system, which were closely associated with major pathogenetic mechanisms underlying AERD.
Authors: Stacey N Reinke; Shama Naz; Romanas Chaleckis; Hector Gallart-Ayala; Johan Kolmert; Nazanin Z Kermani; Angelica Tiotiu; David I Broadhurst; Anders Lundqvist; Henric Olsson; Marika Ström; Åsa M Wheelock; Cristina Gómez; Magnus Ericsson; Ana R Sousa; John H Riley; Stewart Bates; James Scholfield; Matthew Loza; Frédéric Baribaud; Per S Bakke; Massimo Caruso; Pascal Chanez; Stephen J Fowler; Thomas Geiser; Peter Howarth; Ildikó Horváth; Norbert Krug; Paolo Montuschi; Annelie Behndig; Florian Singer; Jacek Musial; Dominick E Shaw; Barbro Dahlén; Sile Hu; Jessica Lasky-Su; Peter J Sterk; Kian Fan Chung; Ratko Djukanovic; Sven-Erik Dahlén; Ian M Adcock; Craig E Wheelock Journal: Eur Respir J Date: 2022-06-30 Impact factor: 33.795
Authors: Ga Young Ban; Young Min Ye; Sang Ha Kim; Gyu Young Hur; Joo Hee Kim; Jae Jung Shim; Kumsun Cho; Joo Youn Cho; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2017-07 Impact factor: 5.764
Authors: Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw Journal: J Allergy Clin Immunol Date: 2021-06-16 Impact factor: 14.290
Authors: Suzy A A Comhair; Grazyna Bochenek; Sara Baicker-McKee; Zeneng Wang; Tomasz Stachura; Marek Sanak; Jeffrey P Hammel; Stanley L Hazen; Serpil C Erzurum; Ewa Nizankowska-Mogilnicka Journal: Respir Res Date: 2018-10-30